I've been forwarding alot of info on Internet addresses and WWW sites where
everyone can get info, and occassionally some specific articles I've found.
Someone recently, who doesn't have WWW access asked if more of the actual
articles could be forwarded, so here's a few. The one site I found had
summaries of over 350 articles, so it'll take a while to get through them
all. Good reading....
**********
Debrisoquine hydroxylase gene polymorphism and susceptibility to
Parkinson's disease.
Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maranganore DM;
Sturman SG; Schapira AH; Williams AC; Spurr NK; et al
Imperial Cancer Research Fund Molecular Pharmacology Group, George Square,
Edinburgh, UK.
Lancet 339: 1375-7 (1992)
Abstract
The pathogenesis of Parkinson's disease may be influenced by genetic and
environmental factors. Cytochrome P450 mono-oxygenases help to protect
against toxic environmental compounds and individual variations in
cytochrome P450 expression might, therefore, influence susceptibility to
environmentally linked diseases. The frequency of mutant CYP2D6 alleles was
studied in 229 patients with Parkinson's disease and 720 controls.
Individuals with a metabolic defect in the cytochrome P450
CYP2D6-debrisoquine hydroxylase gene with the poor metaboliser phenotype
had a 2.54-fold (95% Cl 1.51-4.28) increased risk of Parkinson's disease.
Determination of CYP2D6 phenotype and genotype may help to identify those
at greatest risk of Parkinson's disease and may also help to identify the
environmental or metabolic agents involved in the pathogenesis of this
disease.
Mesh Headings
Cytochrome P-450*
Disease Susceptibility
Genotype
Human
Hydroxylases*
Mutation
Parkinson Disease*
Polymerase Chain Reaction
Polymorphism (Genetics)*
Risk Factors
Unique Identifier: 92284776
Gene Symbols
CYP2D6
Chemical Identifiers (Names)
EC 1.14. (Hydroxylases)
EC 1.14.99.- (debrisoquine 4-hydroxylase)
9035-51-2 (Cytochrome P-450)
***************
Debrisoquine hydroxylase gene polymorphism and susceptibility to
Parkinson's disease.
Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maranganore DM;
Sturman SG; Schapira AH; Williams AC; Spurr NK; et al
Imperial Cancer Research Fund Molecular Pharmacology Group, George Square,
Edinburgh, UK.
Lancet 339: 1375-7 (1992)
Abstract
The pathogenesis of Parkinson's disease may be influenced by genetic and
environmental factors. Cytochrome P450 mono-oxygenases help to protect
against toxic environmental compounds and individual variations in
cytochrome P450 expression might, therefore, influence susceptibility to
environmentally linked diseases. The frequency of mutant CYP2D6 alleles was
studied in 229 patients with Parkinson's disease and 720 controls.
Individuals with a metabolic defect in the cytochrome P450
CYP2D6-debrisoquine hydroxylase gene with the poor metaboliser phenotype
had a 2.54-fold (95% Cl 1.51-4.28) increased risk of Parkinson's disease.
Determination of CYP2D6 phenotype and genotype may help to identify those
at greatest risk of Parkinson's disease and may also help to identify the
environmental or metabolic agents involved in the pathogenesis of this
disease.
Mesh Headings
Cytochrome P-450*
Disease Susceptibility
Genotype
Human
Hydroxylases*
Mutation
Parkinson Disease*
Polymerase Chain Reaction
Polymorphism (Genetics)*
Risk Factors
Unique Identifier: 92284776
Gene Symbols
CYP2D6
Chemical Identifiers (Names)
EC 1.14. (Hydroxylases)
EC 1.14.99.- (debrisoquine 4-hydroxylase)
9035-51-2 (Cytochrome P-450)
*********************
Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second
look.
Tanner CM
Clinical Center for Parkinson's Disease and Movement Disorders, San Jose,
CA 95128.
Neurology 41: 89-91; discussion 92 (1991)
Abstract
If toxicant exposure contributes to the cause of Parkinson's disease, poor
function of detoxifying enzymes could increase vulnerability for
Parkinson's disease. Although no hepatic enzyme system has been shown
universally to be dysfunctional in Parkinson's disease patients, several
have been suggested to be dysfunctional in subgroups, such as those with
young age at disease onset. Specific enzymes implicated include several
P450 enzymes, most notably P450 IID6, and cysteine dioxygenase. If hepatic
enzyme abnormalities contribute to the development of Parkinson's disease,
molecular genetic techniques may allow the development of screening tests
to identify at-risk subjects in order to intervene with protective
therapies.
Mesh Headings
Cytochrome P-450
Debrisoquin
Human
Liver*
Parkinson Disease*
Phenotype
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Unique Identifier: 91251963
Chemical Identifiers (Names)
1131-64-2 (Debrisoquin)
28289-54-5 (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
9035-51-2 (Cytochrome P-450)
**************
Liver enzyme abnormalities in Parkinson's disease.
Tanner CM
Clinical Center for Parkinson's Disease and Movement Disorders, San Jose,
California.
Geriatrics 46 Suppl 1: 60-3 (1991)
Abstract
If toxicant exposure contributes to the cause of Parkinson's disease, poor
function of detoxifying enzymes could increase vulnerability for
Parkinson's disease. Although no hepatic enzyme system has been shown
universally to be dysfunctional in Parkinson's disease patients, several
have been suggested to be dysfunctional in subgroups, such as those with
young age at disease onset. Specific enzymes implicated include several
P450 enzymes, most notably P450 IID6, and cysteine dioxygenase. If hepatic
enzyme abnormalities contribute to the development of Parkinson's disease,
molecular genetic techniques may allow the development of screening tests
to identify at-risk subjects in order to intervene with protective
therapies.
Mesh Headings
Cytochrome P-450
Debrisoquin
Human
Liver*
Parkinson Disease*
Phenotype
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Unique Identifier: 91372608
Chemical Identifiers (Names)
1131-64-2 (Debrisoquin)
28289-54-5 (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
9035-51-2 (Cytochrome P-450)
****************
Parkinson's disease: a genetic study.
Alonso ME; Otero E; D'Regules R; Figueroa HH
Can J Neurol Sci 13: 248-51 (1986)
Abstract
A sample of 122 patients with Parkinson's Disease was studied for the
purpose of investigating if the frequency of relatives affected with
Parkinson in this group was higher than in a control group and to see if
the genetic load was more important in some of the subtypes of Parkinson
described by Barbeau and Pourcher (1982). In our 122 patients, we found
that 1.7% were post-encephalic parkinsonian, 12.3% were symptomatic cases
and 86% of the idiopathic variety. There were 16.1% early onset patients in
the idiopathic group and among these we found 23.5% with a positive family
history of Parkinson in the first-degree relatives. In 6 cases with the
tremor onset form of the disease, the family history was positive and 5
patients, 4.7% had familial essential tremor-related Parkinsonism. Our
results support Barbeau's hypothesis that Parkinson is a heterogeneous
disease in which some subtypes (such as early onset Parkinson) have an
important genetic susceptibility component.
Mesh Headings
Female
Genes, Dominant
Human
Male
Middle Age
Parkinson Disease*
Pedigree
Tremor
Unique Identifier: 86297877
*********
That's enough for now!!
